The Quigley Corporation Announces Phase II Clinical Study on QR-334 Formulation to Relieve Sialorrhea Symptoms

DOYLESTOWN, PA, July 9, 2002 - The Quigley Corporation (NASDAQ: QGLY) today announced that a Phase II Clinical Trial of compound QR-334 will commence later this month. QR-334 is a new formulation being developed and tested by Quigley Pharma Inc. to relieve Sialorrhea (excess secretions of the salivary glands, causing drooling) in patients suffering from diseases including Amyotrophic Lateral Sclerosis (ALS), otherwise known as Lou Gehrig's Disease, Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy among others.

Sialorrhea affects 2,200,000 to 3,500,000 patients annually suffering from these diverse diseases. QR-334 will no longer qualify for Orphan Drug Status as was originally intended, as such new products apply only to a patient population no greater than 200,000. An alternate development path is being pursued for this all-natural formulation.

The Principal Investigator for this trial will be Dr. Stanley H. Appel, Professor and Chairman of the Department of Neurology at the Baylor College of Medicine, Texas Medical Center, in Houston. The Phase II trial will be a multi center U.S. study that will include approximately 100 patients at clinical sites at Baylor College of Medicine, Houston, Texas, the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School (UMDNJ-RWJ) and other private clinical research centers in Philadelphia, Louisville, Tampa and LaJolla, California.

According to Richard Rosenbloom, M.D., PhD, the prospect of an effective and safe natural product represents an important advancement in the treatment of sialorrhea. Dr. Rosenbloom is Vice President of Research & Development for The Quigley Corporation and Executive Vice President, Chief Operating Officer, of Quigley Pharma Inc.

Guy J. Quigley, Chairman, President and Chief Executive Officer of The Quigley Corporation, stated, "We are pleased with the progress being made by Quigley Pharma under the direction of Dr. Rosenbloom. The size of the potential market for new drugs under development through Quigley Pharma offers the prospect of enhanced value for our shareholders in the coming months and for years to come."

The Quigley Corporation (Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.